Clinical performance validation of the STANDARD G6PD test: a multi-country pooled analysis
<p><strong>Introduction:</strong> Screening for G6PD deficiency can inform disease management including malaria. Treatment with the antimalarial drugs primaquine and tafenoquine can be guided by point-of-care testing for G6PD deficiency.</p> <p><strong>Me...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Public Library of Science
2023
|
| _version_ | 1797111633880809472 |
|---|---|
| author | Adissu, W Brito, M Garbin, E Macedo, M Monteiro, W Mukherjee, SK Myburg, J Alam, MS Bancone, G Bansil, P Pal, S Sharma, A Zobrist, S Bryan, A Chu, CS Das, S Domingo, GJ Hann, A Kublin, J Lacerda, MVG Layton, M Ley, B Murphy, SC Nosten, F Pereira, D Price, RN Talukdar, A Yilma, D Gerth-Guyette, E |
| author_facet | Adissu, W Brito, M Garbin, E Macedo, M Monteiro, W Mukherjee, SK Myburg, J Alam, MS Bancone, G Bansil, P Pal, S Sharma, A Zobrist, S Bryan, A Chu, CS Das, S Domingo, GJ Hann, A Kublin, J Lacerda, MVG Layton, M Ley, B Murphy, SC Nosten, F Pereira, D Price, RN Talukdar, A Yilma, D Gerth-Guyette, E |
| author_sort | Adissu, W |
| collection | OXFORD |
| description | <p><strong>Introduction:</strong> Screening for G6PD deficiency can inform disease management including malaria. Treatment with the antimalarial drugs primaquine and tafenoquine can be guided by point-of-care testing for G6PD deficiency.</p>
<p><strong>Methods and findings</strong>: Data from similar clinical studies evaluating the performance of the STANDARD G6PD Test (SD Biosensor, South Korea) conducted in Bangladesh, Brazil, Ethiopia, India, Thailand, the United Kingdom, and the United States were pooled. Test performance was assessed in a retrospective analysis on capillary and venous specimens. All study sites used spectrophotometry for reference G6PD testing, and either the HemoCue or complete blood count for reference hemoglobin measurement. The sensitivity of the STANDARD G6PD Test using the manufacturer thresholds for G6PD deficient and intermediate cases in capillary specimens from 4212 study participants was 100% (95% Confidence Interval (CI): 97.5%–100%) for G6PD deficient cases with <30% activity and 77% (95% CI 66.8%–85.4%) for females with intermediate activity between 30%–70%. Specificity was 98.1% (95% CI 97.6%–98.5%) and 92.8% (95% CI 91.6%–93.9%) for G6PD deficient individuals and intermediate females, respectively. Out of 20 G6PD intermediate females with false normal results, 12 had activity levels >60% on the reference assay. The negative predictive value for females with G6PD activity >60% was 99.6% (95% CI 99.1%–99.8%) on capillary specimens. Sensitivity among 396 <em>P</em>. <em>vivax</em> malaria cases was 100% (69.2%–100.0%) for both deficient and intermediate cases. Across the full dataset, 37% of those classified as G6PD deficient or intermediate resulted from true normal cases. Despite this, over 95% of cases would receive correct treatment with primaquine, over 87% of cases would receive correct treatment with tafenoquine, and no true G6PD deficient cases would be treated inappropriately based on the result of the STANDARD G6PD Test.</p>
<p><strong>Conclusions:</strong> The STANDARD G6PD Test enables safe access to drugs which are contraindicated for individuals with G6PD deficiency. Operational considerations will inform test uptake in specific settings.</p> |
| first_indexed | 2024-03-07T08:11:39Z |
| format | Journal article |
| id | oxford-uuid:cd230264-dab1-46dd-9285-7ced9aab446c |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T08:11:39Z |
| publishDate | 2023 |
| publisher | Public Library of Science |
| record_format | dspace |
| spelling | oxford-uuid:cd230264-dab1-46dd-9285-7ced9aab446c2023-12-01T13:43:19ZClinical performance validation of the STANDARD G6PD test: a multi-country pooled analysisJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:cd230264-dab1-46dd-9285-7ced9aab446cEnglishSymplectic ElementsPublic Library of Science2023Adissu, WBrito, MGarbin, EMacedo, MMonteiro, WMukherjee, SKMyburg, JAlam, MSBancone, GBansil, PPal, SSharma, AZobrist, SBryan, AChu, CSDas, SDomingo, GJHann, AKublin, JLacerda, MVGLayton, MLey, BMurphy, SCNosten, FPereira, DPrice, RNTalukdar, AYilma, DGerth-Guyette, E<p><strong>Introduction:</strong> Screening for G6PD deficiency can inform disease management including malaria. Treatment with the antimalarial drugs primaquine and tafenoquine can be guided by point-of-care testing for G6PD deficiency.</p> <p><strong>Methods and findings</strong>: Data from similar clinical studies evaluating the performance of the STANDARD G6PD Test (SD Biosensor, South Korea) conducted in Bangladesh, Brazil, Ethiopia, India, Thailand, the United Kingdom, and the United States were pooled. Test performance was assessed in a retrospective analysis on capillary and venous specimens. All study sites used spectrophotometry for reference G6PD testing, and either the HemoCue or complete blood count for reference hemoglobin measurement. The sensitivity of the STANDARD G6PD Test using the manufacturer thresholds for G6PD deficient and intermediate cases in capillary specimens from 4212 study participants was 100% (95% Confidence Interval (CI): 97.5%–100%) for G6PD deficient cases with <30% activity and 77% (95% CI 66.8%–85.4%) for females with intermediate activity between 30%–70%. Specificity was 98.1% (95% CI 97.6%–98.5%) and 92.8% (95% CI 91.6%–93.9%) for G6PD deficient individuals and intermediate females, respectively. Out of 20 G6PD intermediate females with false normal results, 12 had activity levels >60% on the reference assay. The negative predictive value for females with G6PD activity >60% was 99.6% (95% CI 99.1%–99.8%) on capillary specimens. Sensitivity among 396 <em>P</em>. <em>vivax</em> malaria cases was 100% (69.2%–100.0%) for both deficient and intermediate cases. Across the full dataset, 37% of those classified as G6PD deficient or intermediate resulted from true normal cases. Despite this, over 95% of cases would receive correct treatment with primaquine, over 87% of cases would receive correct treatment with tafenoquine, and no true G6PD deficient cases would be treated inappropriately based on the result of the STANDARD G6PD Test.</p> <p><strong>Conclusions:</strong> The STANDARD G6PD Test enables safe access to drugs which are contraindicated for individuals with G6PD deficiency. Operational considerations will inform test uptake in specific settings.</p> |
| spellingShingle | Adissu, W Brito, M Garbin, E Macedo, M Monteiro, W Mukherjee, SK Myburg, J Alam, MS Bancone, G Bansil, P Pal, S Sharma, A Zobrist, S Bryan, A Chu, CS Das, S Domingo, GJ Hann, A Kublin, J Lacerda, MVG Layton, M Ley, B Murphy, SC Nosten, F Pereira, D Price, RN Talukdar, A Yilma, D Gerth-Guyette, E Clinical performance validation of the STANDARD G6PD test: a multi-country pooled analysis |
| title | Clinical performance validation of the STANDARD G6PD test: a multi-country pooled analysis |
| title_full | Clinical performance validation of the STANDARD G6PD test: a multi-country pooled analysis |
| title_fullStr | Clinical performance validation of the STANDARD G6PD test: a multi-country pooled analysis |
| title_full_unstemmed | Clinical performance validation of the STANDARD G6PD test: a multi-country pooled analysis |
| title_short | Clinical performance validation of the STANDARD G6PD test: a multi-country pooled analysis |
| title_sort | clinical performance validation of the standard g6pd test a multi country pooled analysis |
| work_keys_str_mv | AT adissuw clinicalperformancevalidationofthestandardg6pdtestamulticountrypooledanalysis AT britom clinicalperformancevalidationofthestandardg6pdtestamulticountrypooledanalysis AT garbine clinicalperformancevalidationofthestandardg6pdtestamulticountrypooledanalysis AT macedom clinicalperformancevalidationofthestandardg6pdtestamulticountrypooledanalysis AT monteirow clinicalperformancevalidationofthestandardg6pdtestamulticountrypooledanalysis AT mukherjeesk clinicalperformancevalidationofthestandardg6pdtestamulticountrypooledanalysis AT myburgj clinicalperformancevalidationofthestandardg6pdtestamulticountrypooledanalysis AT alamms clinicalperformancevalidationofthestandardg6pdtestamulticountrypooledanalysis AT banconeg clinicalperformancevalidationofthestandardg6pdtestamulticountrypooledanalysis AT bansilp clinicalperformancevalidationofthestandardg6pdtestamulticountrypooledanalysis AT pals clinicalperformancevalidationofthestandardg6pdtestamulticountrypooledanalysis AT sharmaa clinicalperformancevalidationofthestandardg6pdtestamulticountrypooledanalysis AT zobrists clinicalperformancevalidationofthestandardg6pdtestamulticountrypooledanalysis AT bryana clinicalperformancevalidationofthestandardg6pdtestamulticountrypooledanalysis AT chucs clinicalperformancevalidationofthestandardg6pdtestamulticountrypooledanalysis AT dass clinicalperformancevalidationofthestandardg6pdtestamulticountrypooledanalysis AT domingogj clinicalperformancevalidationofthestandardg6pdtestamulticountrypooledanalysis AT hanna clinicalperformancevalidationofthestandardg6pdtestamulticountrypooledanalysis AT kublinj clinicalperformancevalidationofthestandardg6pdtestamulticountrypooledanalysis AT lacerdamvg clinicalperformancevalidationofthestandardg6pdtestamulticountrypooledanalysis AT laytonm clinicalperformancevalidationofthestandardg6pdtestamulticountrypooledanalysis AT leyb clinicalperformancevalidationofthestandardg6pdtestamulticountrypooledanalysis AT murphysc clinicalperformancevalidationofthestandardg6pdtestamulticountrypooledanalysis AT nostenf clinicalperformancevalidationofthestandardg6pdtestamulticountrypooledanalysis AT pereirad clinicalperformancevalidationofthestandardg6pdtestamulticountrypooledanalysis AT pricern clinicalperformancevalidationofthestandardg6pdtestamulticountrypooledanalysis AT talukdara clinicalperformancevalidationofthestandardg6pdtestamulticountrypooledanalysis AT yilmad clinicalperformancevalidationofthestandardg6pdtestamulticountrypooledanalysis AT gerthguyettee clinicalperformancevalidationofthestandardg6pdtestamulticountrypooledanalysis |